These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 15113989)

  • 1. Cost-effectiveness of escitalopram versus citalopram in the treatment of severe depression.
    Hemels ME; Kasper S; Walter E; Einarson TR
    Ann Pharmacother; 2004 Jun; 38(6):954-60. PubMed ID: 15113989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A pharmacoeconomic evaluation of escitalopram versus citalopram in the treatment of severe depression in the United Kingdom.
    Wade AG; Toumi I; Hemels ME
    Clin Ther; 2005 Apr; 27(4):486-96. PubMed ID: 15922821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness analysis of escitalopram: a new SSRI in the first-line treatment of major depressive disorder in Austria.
    Hemels ME; Kasper S; Walter E; Einarson TR
    Curr Med Res Opin; 2004 Jun; 20(6):869-78. PubMed ID: 15200745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A cost-effectiveness model of escitalopram, citalopram,and venlafaxine as first-line treatment for major depressive disorder in Belgium.
    Demyttenaere K; Hemels ME; Hudry J; Annemans L
    Clin Ther; 2005 Jan; 27(1):111-24. PubMed ID: 15763612
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spotlight on the pharmacoeconomics of escitalopram in depression.
    Croom KF; Plosker GL
    CNS Drugs; 2004; 18(7):469-73. PubMed ID: 15139801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A probabilistic cost-effectiveness analysis of escitalopram, generic citalopram and venlafaxine as a first-line treatment of major depressive disorder in the UK.
    Wade AG; Toumi I; Hemels ME
    Curr Med Res Opin; 2005 Apr; 21(4):631-42. PubMed ID: 15899113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Escitalopram and duloxetine in major depressive disorder: a pharmacoeconomic comparison using UK cost data.
    Wade AG; Fernández JL; François C; Hansen K; Danchenko N; Despiegel N
    Pharmacoeconomics; 2008; 26(11):969-81. PubMed ID: 18850765
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Escitalopram: a pharmacoeconomic review of its use in depression.
    Croom KF; Plosker GL
    Pharmacoeconomics; 2003; 21(16):1185-209. PubMed ID: 14594439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of escitalopram vs. citalopram in major depressive disorder.
    Fantino B; Moore N; Verdoux H; Auray JP
    Int Clin Psychopharmacol; 2007 Mar; 22(2):107-15. PubMed ID: 17293711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Danish cost-effectiveness model of escitalopram in comparison with citalopram and venlafaxine as first-line treatments for major depressive disorder in primary care.
    Sørensen J; Stage KB; Damsbo N; Le Lay A; Hemels ME
    Nord J Psychiatry; 2007; 61(2):100-8. PubMed ID: 17454724
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A budget-impact and cost-effectiveness model for second-line treatment of major depression.
    Malone DC
    J Manag Care Pharm; 2007 Jul; 13(6 Suppl A):S8-18. PubMed ID: 17874482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Escitalopram in the treatment of major depressive disorder: clinical efficacy, tolerability and cost-effectiveness vs. venlafaxine extended-release formulation.
    Llorca PM; Fernandez JL
    Int J Clin Pract; 2007 Apr; 61(4):702-10. PubMed ID: 17394446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-utility comparison of escitalopram and sertraline in the treatment of major depressive disorder.
    Armstrong EP; Skrepnek GH; Haim Erder M
    Curr Med Res Opin; 2007 Feb; 23(2):251-8. PubMed ID: 17288678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost effectiveness of escitalopram versus SNRIs in second-step treatment of major depressive disorder in Sweden.
    Nordström G; Despiegel N; Marteau F; Danchenko N; Maman K
    J Med Econ; 2010; 13(3):516-26. PubMed ID: 20698748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Escitalopram is more effective than citalopram for the treatment of severe major depressive disorder].
    Azorin JM; Llorca PM; Despiegel N; Verpillat P
    Encephale; 2004; 30(2):158-66. PubMed ID: 15107719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The treatment of major depressive disorders (MDD) in Thailand using escitalopram compared to fluoxetine and venlafaxine: a pharmacoeconomic evaluation.
    Kongsakon R; Bunchapattanasakda C
    J Med Assoc Thai; 2008 Jul; 91(7):1117-28. PubMed ID: 18839855
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of outpatient treatment in depressive patients with escitalopram in Germany.
    Kulp W; von der Schulenburg JM; Greiner W
    Eur J Health Econ; 2005 Dec; 6(4):317-21. PubMed ID: 16267659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of escitalopram in major depressive disorder in the Dutch health care setting.
    Nuijten MJ; Brignone M; Marteau F; den Boer JA; Hoencamp E
    Clin Ther; 2012 Jun; 34(6):1364-78. PubMed ID: 22578310
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence based review of escitalopram in treating major depressive disorder in primary care.
    Einarson TR
    Int Clin Psychopharmacol; 2004 Sep; 19(5):305-10. PubMed ID: 15289704
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Healthcare expenditure in severely depressed patients treated with escitalopram, generic SSRIs or venlafaxine in the UK.
    Wade AG; Saragoussi D; Despiégel N; François C; Guelfucci F; Toumi M
    Curr Med Res Opin; 2010 May; 26(5):1161-70. PubMed ID: 20297951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.